Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Classifica tra le azioni
#3418
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Prezzo delle azioni
$4.48
Capitalizzazione di mercato
$4.99B
Variazione (1 giorno)
-5.20%
Variazione (1 anno)
-41.89%
Paese
CN
Scambia Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Categoria
Healthcare
Margine operativo per Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Margine operativo al October 2026 TTM: 10.66%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Shenzhen Salubris Pharmaceuticals Co., Ltd., il margine operativo attuale (TTM) è 10.66%. Alla fine del 2024, il margine operativo era 16.11%.
Storico del margine operativo per Shenzhen Salubris Pharmaceuticals Co., Ltd. da 2006 a 2026
Margine operativo alla fine di ogni anno
| Anno | Margine Operativo | Cambia |
|---|---|---|
| 2026 (TTM) | 10.66% | -26.94% |
| 2025 | 14.59% | -9.44% |
| 2024 | 16.11% | -17.34% |
| 2023 | 19.49% | -6.70% |
| 2022 | 20.89% | 8.97% |
| 2021 | 19.17% | 563.32% |
| 2020 | 2.89% | -84.73% |
| 2019 | 18.93% | -48.80% |
| 2018 | 36.97% | -10.44% |
| 2017 | 41.28% | -2.92% |
| 2016 | 42.52% | 0.02% |
| 2015 | 42.51% | 1.50% |
| 2014 | 41.88% | 0.72% |
| 2013 | 41.58% | 7.03% |
| 2012 | 38.85% | 27.80% |
| 2011 | 30.40% | -4.40% |
| 2010 | 31.80% | 9.96% |
| 2009 | 28.92% | 20.90% |
| 2008 | 23.92% | 9.78% |
| 2007 | 21.79% | 18.55% |
| 2006 | 18.38% | 0.00% |
Margine operativo per aziende simili o concorrenti
| Azienda | Margine Operativo | Differenza del margine operativo | Il paese |
|---|---|---|---|
| 28.37% | -97.34% |
US
|
|
| 12.36% | -98.84% |
FR
|
|
| 30.18% | -97.17% |
JP
|
|
| 9.83% | -99.08% |
US
|
|
| 9.87% | -99.07% |
CH
|
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.